Beilerli, A.,
Kudriashov, V.,
Sufianov, A.,
Kostin, A.,
Begliarzade, S.,
Ilyasova, T.,
Liang, Ya.,
Mukhamedzyanov, A.,
Beylerli, O. (2023) RNAs) as dynamic
modifiers in the pathogenesis of various
diseases. MiRNAs are a separate class of RNA molecules
Shnayder, N.A.,
Grechkina, V.V.,
Khasanova, A.K.,
Bochanova, E.N.,
Dontceva, E.A.,
Petrova, M.M.,
Asadullin, A.R.,
Shipulin, G.A.,
Altynbekov, K.S.,
Al-Zamil, M.,
Nasyrova, R.F. (2023) of therapeutic and toxic metabolites of VPA in the human body. Thus, VPA is considered a component of
disease-modifyingSharipov, R.A.,
Omarov, M.A.,
Mulyukov, A.R.,
Dybova, A.I.,
Vyaseleva, E.T.,
Kayumova, N.B.,
Saitgalina, A. Sh.,
Ententeev, K.R.,
Iagafarov, I.R.,
Kuserbaev, I.V.,
Gubaeva, E.A. (2023) of gene
therapy methods and attracted the attention of the entire scientific community. This technology
of these miRNAs during aging and various
diseases, such
as cancer and difficult-to-treat
diseases. The use
Sufianov, A.,
Kostin, A.,
Begliarzade, S.,
Kudriashov, V.,
Ilyasova, T.,
Liang, Y.,
Mukhamedzyanov, A.,
Beylerli, O. (2023) of damage to the cardiovascular system, which in turn leads to
diseases such as myocardial infarction
investigations and clinical
trials employed enhanced MSCs-dependent
therapies in treatment of inflammatory